Enrolling by invitationPHASE2, PHASE3NCT03802799
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
Studying Fragile X syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zynerba Pharmaceuticals, Inc.
- Intervention
- ZYN002 - Cannabidiol Transdermal Gel(drug)
- Enrollment
- 550 enrolled
- Eligibility
- 3-29 years · All sexes
- Timeline
- 2018 – 2027
Study locations (26)
- Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
- Science 37, Culver City, California, United States
- Amnova Clinical Research, LLC, Irvine, California, United States
- UC Davis Health System, MIND Institute, Sacramento, California, United States
- Children's Hospital of Colorado, Denver, Colorado, United States
- Children's Research Institute, Washington D.C., District of Columbia, United States
- University of Miami, Miami, Florida, United States
- Han Phan, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Masonic Institute of Developing Brain, Minneapolis, Minnesota, United States
- University of Mississipi Medical Center, Jackson, Mississippi, United States
- The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03802799 on ClinicalTrials.govOther trials for Fragile X syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07493096Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal DisordersHealing Hope International
- RECRUITINGPHASE2NCT07209462Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)Mirum Pharmaceuticals, Inc.
- RECRUITINGNANCT06868979Optical Imaging in X-linked Disorders.Hospices Civils de Lyon
- RECRUITINGNANCT06740162Physical Activity and Community EmPOWERment ProjectUniversity of North Carolina, Chapel Hill
- RECRUITINGPHASE2NCT06081348Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersHolland Bloorview Kids Rehabilitation Hospital
- RECRUITINGNANCT06279858Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X SyndromeSpecila hospital for cerebral palsy and developmental neurology
- RECRUITINGNANCT06088589Speech-in-noise Perception in Autism and Fragile XChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNANCT06139172Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)Rush University Medical Center